Amgen, Inc. (NASDAQ:AMGN)

CAPS Rating: 4 out of 5

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Results 1 - 20 of 341 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Yobberman (< 20) Submitted: 5/28/2015 9:30:50 PM : Outperform Start Price: $156.79 AMGN Score: +13.24

It's a good-lookin' stock

Recs

0
Member Avatar Kimer62 (52.76) Submitted: 5/9/2015 8:43:24 AM : Outperform Start Price: $160.98 AMGN Score: +10.01

value and conservative

Recs

0
Member Avatar Herbstmd (58.28) Submitted: 4/17/2015 8:39:24 PM : Outperform Start Price: $163.83 AMGN Score: +6.86

New drugs in testing include a possible block buster new cholesterol treatment that will out do the entire statin field. A real blockbuster. Akso nice dividend. I see this as stable and rising with the PE of 24 readonable.

Recs

0
Member Avatar Neowalkit (31.78) Submitted: 4/2/2015 2:13:35 PM : Outperform Start Price: $155.73 AMGN Score: +11.28

It has performed well in the past and I don't see that there is any reason for it to change

Recs

0
Member Avatar mobiusstrip (57.86) Submitted: 4/1/2015 12:00:08 PM : Outperform Start Price: $156.34 AMGN Score: +10.18

Been watching this stock for years and frustrated as it kept going up each time I wanted to buy, but not pulling the trigger. Dividend growth is fantastic, and I can jump in at a 2% yield today after 2 straight down days. Earnings expected to be well over $10/share within a year or two, so a doubling of the dividend or more in the next 3 years is entirely supported by income growth.

Recs

0
Member Avatar TMFTypeoh (84.16) Submitted: 3/24/2015 9:08:50 PM : Outperform Start Price: $165.18 AMGN Score: +5.99

Company is set on increasing operating margin by cutting costs and increasing prices. New drugs on the way should boost revenue and a buyback with a fast growing dividend should propel Amgen ever higher.

Recs

0
Member Avatar factoids (67.88) Submitted: 3/20/2015 11:00:52 AM : Outperform Start Price: $168.69 AMGN Score: +4.41

AMGN has high dividend and EPS growth at a reasonable yield

Recs

0
Member Avatar CellBlock9 (91.95) Submitted: 2/8/2015 12:09:57 PM : Outperform Start Price: $148.48 AMGN Score: +15.84

mgk, S&P 4 star

Recs

0
Member Avatar manirg (95.97) Submitted: 2/5/2015 11:13:33 AM : Outperform Start Price: $149.82 AMGN Score: +15.19

undervalued, a super pipeline

Recs

0
Member Avatar TheDumbMoney (60.46) Submitted: 1/26/2015 11:01:54 AM : Outperform Start Price: $159.34 AMGN Score: +7.87

Bought 30 shares at $159.62, in IRA, no commission.

Recs

1
Member Avatar handballjones (< 20) Submitted: 1/14/2015 9:13:37 PM : Outperform Start Price: $154.57 AMGN Score: +9.58

Pipeline has a lot of pent up pop pending, the company has become very dynamic while now watching costs, plus looks to be sharing more wealth with it stakeholder (shareholders).

Recs

1
Member Avatar Rayliu25 (< 20) Submitted: 12/10/2014 4:06:11 PM : Outperform Start Price: $165.01 AMGN Score: +3.54

Leading the biotech revolution

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 5/13/2014 1:33:33 PM : Outperform Start Price: $109.61 AMGN Score: +48.33

Div. (Yield) $2.44 (2.2%)

Recs

0
Member Avatar tbittker (< 20) Submitted: 5/11/2014 11:50:10 AM : Outperform Start Price: $109.10 AMGN Score: +49.83

Extensive patents. Demographics positive. May have a breakthrough drug in lipid control.

Recs

0
Member Avatar dswallen (36.88) Submitted: 4/24/2014 1:21:55 PM : Outperform Start Price: $111.43 AMGN Score: +46.09

Dividend growth + several great drugs already on the market + a great pipeline. This is the best name in Biotech.

Recs

0
Member Avatar TerryHoodSr (77.01) Submitted: 4/15/2014 9:52:51 AM : Outperform Start Price: $112.59 AMGN Score: +42.09

trade buy@ 113 TP 129

Recs

0
Member Avatar Dividends500 (89.73) Submitted: 3/26/2014 4:37:49 PM : Outperform Start Price: $117.13 AMGN Score: +33.50

Dividends500 tracks the 200 strongest dividends in the S&P 500. To qualify as a strong dividend, the company must meet two simple requirements:

- A payout ratio below 50%
- An increasing dividend from the prior year

Because there are more than 200 dividend paying companies in the S&P 500 that meet these requirements, the qualifying companies with the largest dividend yields were chosen.

Dividends500 intends to test this FactSet article, which highlights these strong dividend paying companies and their outperformance versus the S&P 500 as a whole (Page 12).

http://www.factset.com/websitefiles/PDFs/dividend/dividend_12.16.13

If you have questions or see something you think is inaccurate feel free to let me know.

Recs

0
Member Avatar TerryFool (62.56) Submitted: 2/25/2014 9:41:55 AM : Outperform Start Price: $116.95 AMGN Score: +37.75

AMGN BP 115 TP 131 REV 1yr 10% EPS 1yr 16%

Recs

0
Member Avatar jcpalmer (< 20) Submitted: 2/13/2014 10:53:03 AM : Outperform Start Price: $120.19 AMGN Score: +31.08

NYT just published an article about Amgen research
on diabetes using grizzly bears while hibernating. This could lead to new and effective treatments for this most important unmet need.

Recs

0
Member Avatar charlie3brown (< 20) Submitted: 2/7/2014 8:02:08 PM : Outperform Start Price: $64.88 AMGN Score: +116.22

This was one of the first stocks I invested in when attending college back in the early 1980s. It helped me pay my rent bill back then. Biotech stocks are very high risk. A novice will probably be safer investing in one of the many index funds now available.

Featured Broker Partners


Advertisement